Top-Rated StocksTop-RatedNASDAQ:ACLX Arcellx (ACLX) Stock Forecast, Price & News $44.15 +0.48 (+1.10%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$43.49▼$45.6650-Day Range$27.49▼$46.9052-Week Range$11.55▼$48.92Volume869,345 shsAverage Volume476,672 shsMarket Capitalization$2.12 billionP/E RatioN/ADividend YieldN/APrice Target$50.38 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Arcellx MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside14.1% Upside$50.38 Price TargetShort InterestBearish22.12% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.51Based on 6 Articles This WeekInsider TradingSelling Shares$76.34 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.20) to ($2.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.66 out of 5 starsMedical Sector886th out of 1,006 stocksBiological Products, Except Diagnostic Industry145th out of 167 stocks 3.5 Analyst's Opinion Consensus RatingArcellx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $50.38, Arcellx has a forecasted upside of 14.1% from its current price of $44.15.Amount of Analyst CoverageArcellx has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted22.12% of the float of Arcellx has been sold short.Short Interest Ratio / Days to CoverArcellx has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.Change versus previous monthShort interest in Arcellx has recently increased by 5.38%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcellx does not currently pay a dividend.Dividend GrowthArcellx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACLX. Previous Next 2.0 News and Social Media Coverage News SentimentArcellx has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Arcellx this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for ACLX on MarketBeat in the last 30 days. This is a decrease of -77% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcellx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $76,338,911.00 in company stock.Percentage Held by Institutions91.78% of the stock of Arcellx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arcellx are expected to decrease in the coming year, from ($1.20) to ($2.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcellx is -10.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcellx is -10.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcellx has a P/B Ratio of 6.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Arcellx (NASDAQ:ACLX) StockArcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.Read More Receive ACLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcellx and its competitors with MarketBeat's FREE daily newsletter. Email Address ACLX Stock News HeadlinesMay 28, 2023 | sg.finance.yahoo.comArcellx, Inc. (ACLX) stock price, news, quote & history – Yahoo FinanceMay 28, 2023 | americanbankingnews.comInsider Selling: Arcellx, Inc. (NASDAQ:ACLX) CFO Sells $369,571.84 in StockMay 31, 2023 | Behind the Markets (Ad)"The $51 Billion Laser Revolution"See how a new contract with the Pentagon could spark a 2,476% sales surge for a small laser firm >>>May 21, 2023 | americanbankingnews.comArcellx (NASDAQ:ACLX) Research Coverage Started at Truist FinancialMay 18, 2023 | msn.comThe Latest Analyst Ratings for ArcellxMay 18, 2023 | msn.comTruist Securities Initiates Coverage of Arcellx (ACLX) with Buy RecommendationMay 17, 2023 | americanbankingnews.comSr One Capital Management, Llc Sells 1,012,833 Shares of Arcellx, Inc. (NASDAQ:ACLX) StockMay 17, 2023 | americanbankingnews.comJill Carroll Sells 638,417 Shares of Arcellx, Inc. (NASDAQ:ACLX) StockMay 31, 2023 | Behind the Markets (Ad)WARNING TO ALL U.S. INVESTORSMay 16, 2023... The Day That Will Financially Paralyze 181 Million American Investors... Here are 3 steps to prepare yourself >>>May 17, 2023 | americanbankingnews.comArcellx, Inc. (NASDAQ:ACLX) Short Interest UpdateMay 16, 2023 | markets.businessinsider.comArcellx Inc (ACLX) Receives a Buy from Stifel NicolausMay 16, 2023 | americanbankingnews.comArcellx, Inc. (NASDAQ:ACLX) Receives Consensus Recommendation of "Buy" from AnalystsMay 14, 2023 | americanbankingnews.comInsider Selling: Arcellx, Inc. (NASDAQ:ACLX) Insider Sells $22,500.00 in StockMay 13, 2023 | americanbankingnews.comQ2 2023 Earnings Estimate for Arcellx, Inc. Issued By William Blair (NASDAQ:ACLX)May 13, 2023 | americanbankingnews.comHC Wainwright Comments on Arcellx, Inc.'s Q2 2023 Earnings (NASDAQ:ACLX)May 12, 2023 | msn.comB of A Securities Maintains Arcellx (ACLX) Buy RecommendationMay 12, 2023 | americanbankingnews.comNeedham & Company LLC Boosts Arcellx (NASDAQ:ACLX) Price Target to $51.00May 11, 2023 | americanbankingnews.comArcellx (NASDAQ:ACLX) Price Target Increased to $50.00 by Analysts at Bank of AmericaMay 11, 2023 | americanbankingnews.comArcellx (NASDAQ:ACLX) Price Target Raised to $49.00 at HC WainwrightMay 10, 2023 | finance.yahoo.comResults: Arcellx, Inc. Delivered A Surprise Loss And Now Analysts Have New ForecastsMay 10, 2023 | americanbankingnews.comInsider Selling: Arcellx, Inc. (NASDAQ:ACLX) Insider Sells 1,200 Shares of StockMay 10, 2023 | marketwatch.com8-K: Arcellx, Inc.May 9, 2023 | msn.comBarclays Maintains Arcellx (ACLX) Overweight RecommendationMay 9, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Arcellx Inc (ACLX)May 9, 2023 | msn.comHC Wainwright & Co. Maintains Arcellx (ACLX) Buy RecommendationMay 9, 2023 | americanbankingnews.comBarclays Boosts Arcellx (NASDAQ:ACLX) Price Target to $49.00May 8, 2023 | finance.yahoo.comArcellx, Inc. (ACLX) Reports Q1 Loss, Misses Revenue EstimatesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ACLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcellx and its competitors with MarketBeat's FREE daily newsletter. Email Address ACLX Company Calendar Last Earnings3/29/2023Today5/31/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACLX CUSIPN/A CIK1786205 Webarcellx.com Phone240-327-0603FaxN/AEmployees78Year FoundedN/APrice Target and Rating Average Stock Price Forecast$50.38 High Stock Price Forecast$104.00 Low Stock Price Forecast$34.00 Forecasted Upside/Downside+11.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($4.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-188,680,000.00 Net MarginsN/A Pretax Margin-1,058.80% Return on Equity-47.99% Return on Assets-31.10% Debt Debt-to-Equity Ratio0.05 Current Ratio3.44 Quick Ratio3.44 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.33 per share Price / Book7.15Miscellaneous Outstanding Shares48,000,000Free FloatN/AMarket Cap$2.17 billion OptionableNot Optionable Beta-0.33 Key ExecutivesMr. Rami Elghandour (Age 44)Chairman, CEO & Pres Comp: $803.97kMr. Neeraj P. Teotia (Age 48)Chief Commercial Officer Comp: $461.95kDr. Christopher R. Heery M.D. (Age 43)Chief Medical Officer Comp: $629.92kMs. Michelle Lim Gilson (Age 31)Chief Financial Officer Mr. Michael Dombeck M.B.A.Chief Operating OfficerMr. Narinderjeet Singh M.S. (Age 51)Chief Technical Officer Mr. David Tice Ph.D. (Age 52)Chief Scientific Officer Ms. Myesha LacyVP of Investor RelationsMs. Maryam Abdul-Kareem J.D.M.S., Gen. CounselMs. Kate AikenChief People OfficerMore ExecutivesKey CompetitorsIovance BiotherapeuticsNASDAQ:IOVAImmunocoreNASDAQ:IMCRBeam TherapeuticsNASDAQ:BEAMSpringWorks TherapeuticsNASDAQ:SWTXRecursion PharmaceuticalsNASDAQ:RXRXView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 911 shares on 5/26/2023Ownership: 0.014%Michelle GilsonSold 8,704 sharesTotal: $369,571.84 ($42.46/share)Putnam Investments LLCBought 34,266 shares on 5/22/2023Ownership: 0.112%JPMorgan Chase & Co.Sold 194,801 shares on 5/18/2023Ownership: 1.144%New York State Common Retirement FundSold 6,991 shares on 5/18/2023Ownership: 0.031%View All Insider TransactionsView All Institutional Transactions ACLX Stock - Frequently Asked Questions Should I buy or sell Arcellx stock right now? 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcellx in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACLX shares. View ACLX analyst ratings or view top-rated stocks. What is Arcellx's stock price forecast for 2023? 11 brokers have issued 12 month target prices for Arcellx's stock. Their ACLX share price forecasts range from $34.00 to $104.00. On average, they anticipate the company's stock price to reach $50.38 in the next year. This suggests a possible upside of 11.3% from the stock's current price. View analysts price targets for ACLX or view top-rated stocks among Wall Street analysts. How have ACLX shares performed in 2023? Arcellx's stock was trading at $30.98 at the beginning of the year. Since then, ACLX stock has increased by 46.2% and is now trading at $45.28. View the best growth stocks for 2023 here. When is Arcellx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our ACLX earnings forecast. How were Arcellx's earnings last quarter? Arcellx, Inc. (NASDAQ:ACLX) announced its quarterly earnings results on Wednesday, March, 29th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by $0.05. What ETFs hold Arcellx's stock? ETFs with the largest weight of Arcellx (NASDAQ:ACLX) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC) and Invesco Nasdaq Biotechnology ETF (IBBQ). When did Arcellx IPO? (ACLX) raised $132 million in an initial public offering on Friday, February 4th 2022. The company issued 8,250,000 shares at $15.00-$17.00 per share. What is Arcellx's stock symbol? Arcellx trades on the NASDAQ under the ticker symbol "ACLX." Who are Arcellx's major shareholders? Arcellx's stock is owned by a number of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (8.00%), FMR LLC (5.61%), Suvretta Capital Management LLC (5.00%), BlackRock Inc. (4.64%), State Street Corp (3.91%) and Pictet Asset Management SA (2.15%). Insiders that own company stock include Christopher Heery, Enterprise Associates 15 New, Jill Carroll, Michelle Gilson, Scott D Sandell and Sr One Capital Management, Llc. View institutional ownership trends. How do I buy shares of Arcellx? Shares of ACLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arcellx's stock price today? One share of ACLX stock can currently be purchased for approximately $45.28. How much money does Arcellx make? Arcellx (NASDAQ:ACLX) has a market capitalization of $2.17 billion. The company earns $-188,680,000.00 in net income (profit) each year or ($4.34) on an earnings per share basis. How can I contact Arcellx? The official website for the company is arcellx.com. The company can be reached via phone at 240-327-0603 or via email at ir@arcellx.com. This page (NASDAQ:ACLX) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcellx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.